September 25, 2025 — Shares of major European medical technology companies slid sharply on Thursday after the United States government announced a wide-ranging investigation into imports of medical devices. The probe, spearheaded by the U.S. Department of Commerce, could ultimately pave the way for the imposition of new tariffs, and has stoked fears of disruptions across the global healthcare ecosystem.

The Section 232 investigation, which references a key provision of U.S. trade law, is evaluating whether the importation of medical devices and related products represents a threat to U.S. national security. Products under review range from diagnostic equipment and surgical instruments to personal protective equipment and critical care machinery such as ventilators and infusion pumps.

Immediate Market Reaction

Following the announcement, shares of prominent European medtech firms—including Siemens Healthineers, Smith & Nephew, Philips, and Sartorius—fell by 4% to 9% in early trading. The STOXX Europe 600 Health Care index lost over 3%, marking its steepest one-day drop in more than a year. Analysts at Barclays and Morgan Stanley noted that the U.S. investigation injects new uncertainty into a sector already navigating post-pandemic supply chain strains and tighter regulatory scrutiny.

Siemens Healthineers (ETR:SHL), one of the world’s largest suppliers of diagnostic and imaging equipment, saw its stock fall over 5%, erasing nearly $4 billion in market capitalization. Philips (AMS:PHIA), whose U.S. sales comprise a significant portion of its revenue, lost nearly 7% as investors braced for possible market access barriers.

Scope of the U.S. Probe

The U.S. Department of Commerce stated that the investigation will focus on the security and resilience of supply chains for critical medical devices, especially amid increasingly complex geopolitical environments. Over the past two years, the United States has raised concerns about overreliance on foreign suppliers—particularly from China and Europe—for key components in its healthcare system.

The probe is also triggered by ongoing post-pandemic demand for medical equipment, pressure to nearshore production, and recent cybersecurity incidents involving hospital IT systems and device firmware. U.S. manufacturers have lobbied for greater domestic protection, arguing that unfair competition and supply chain exposure could hinder preparedness for future health crises.

Analysts project that Europe accounts for approximately $34 billion in U.S. medical device imports annually, representing around 32% of the total U.S. import market for this sector (U.S. International Trade Administration, 2024).

Industry and Government Reactions

European medtech associations, including MedTech Europe, have urgently called for dialogue with both U.S. and EU regulators to avoid any “widespread and unnecessary barriers” in global healthcare delivery. In a statement, MedTech Europe said, “Access to safe and efficient medical technologies should not become collateral damage in broader trade disputes.”

The European Commission has pledged to monitor the situation closely and expressed concerns over potential retaliatory measures. An EU spokesperson said, “The European Union stands ready to defend the interests of its medical technology industry and to coordinate with partners to safeguard patient access to vital products.”

Some U.S. hospital groups and device distributors also voiced worries that new tariffs could increase costs for American healthcare providers, limit access to innovative technologies, and worsen ongoing shortages in certain equipment categories.

Wider Trade and Geopolitical Implications

This move comes as trade tensions between the U.S. and Europe intensify, even as both regions seek closer collaboration in advanced manufacturing and life sciences. The Biden administration’s prior actions on semiconductors and battery imports—also justified under Section 232—set important precedents for policy direction and potential retaliatory action.

Apart from medical equipment, other categories recently targeted in sweeping U.S. import investigations include robotics, personal protective equipment, masks, and syringes. The cumulative effect has raised concerns of an impending wave of tit-for-tat tariffs, with implications for the $780 billion U.S.-EU trade corridor.

Many multinationals have already begun contingency planning. Consulting firms such as McKinsey and Deloitte are advising both European and U.S. device makers to assess supply chain vulnerabilities, diversify critical manufacturing activities, and prepare for a more fragmented regulatory environment.

Healthcare Supply Chain Strains

The prospect of new tariffs or export controls threatens not just corporate profits but also the resilience of global healthcare systems. Hospitals in both the U.S. and Europe have warned that delays or cost overruns in obtaining advanced diagnostic or life-saving equipment could affect patient outcomes, especially given the aging populations in both markets.

Recent data from the U.S. Centers for Medicare and Medicaid Services (CMS) show a continued spike in demand for imaging and critical care devices, with utilization rates up nearly 8% in 2024–2025 compared to pre-pandemic levels. Shortages of certain items—including high-precision diagnostic assays and ventilator components—have already been reported in some regions, exacerbated by pandemic-era disruptions and geopolitical uncertainty.

What’s Next?

The U.S. Commerce Department has set a preliminary comment period of 60 days for industry stakeholders to submit feedback. A final decision on potential tariff measures is expected by early 2026. Meanwhile, European regulators are weighing possible legal complaints at the World Trade Organization if U.S. actions are deemed discriminatory or unjustified.

For medtech investors and corporate strategists, the coming months will be critical in assessing where production and R&D investments can be best allocated amid shifting trade realignments. As the probe unfolds, attention will remain fixed on both diplomatic negotiations and healthcare supply chain dashboards worldwide.